David B. Sykes

David B. Sykes, MD, PhD

Instructor in Medicine,

Harvard Medical School

David joined the MGH Cancer Center as an attending in benign hematology. He splits his time between the laboratory (80% research) and clinic (20% direct patient care). He sees patients with all diagnoses with a focus on patients with myeloproliferative disorders.

David has a special interest in rare hematologic conditions. In 2011 he defined a new syndrome – the TEMPI syndrome – which affects only 9 identified patients worldwide.

David’s research involves understanding and identifying new treatments for acute myeloid leukemia. His research is currently being carried out in the lab of Dr. David Scadden. He is focused on designing drugs for patients with acute myeloid leukemia that trigger differentiation, or maturation, of the leukemic cells.

David completed his undergraduate training in Biochemistry at the University of Alberta in Edmonton, Canada. He entered the Medical Scientist Training Program (M.D., Ph.D.) at the University of California San Diego and carried out his Ph.D. research with Dr. Mark Kamps. David did his internship and residency at the Massachusetts General Hospital as well as a year as a Chief Medical Resident in the Department of Internal Medicine. He was a Hematology and Oncology fellow in the combined Dana-Farber Cancer Institute, MGH Cancer Center fellowship program. Dr. Sykes is Board Certified in Internal Medicine,

Hematology, and Medical Oncology.